Posted by Michael Wonder on 29 Apr 2019
Zynquista now approved in the European Union for treatment of adults with type 1 diabetes
27 April 2019 - The European Commission has granted marketing authorisation for Zynquista (sotagliflozin), developed by Sanofi and Lexicon.
Zynquista is now approved in the European Union, at once-daily doses of 200 mg and 400 mg, for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes mellitus and a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy.
